Cash, cash equivalents, and marketable securities totaled $167.6 million as of June 30, with runway into the first half of 2028.
The Phase 1 dose-escalation trial for FHD-909 (LY4050784) is advancing with NSCLC as the primary target; selective EP300 degraders remain on track for a 2027 IND.
Q2 net loss narrows as collaboration revenue increases
Foghorn Therapeutics posted a Q2 net loss of $7.2 million, narrowing from a $17.9 million loss a year earlier.
Collaboration revenue rose to $16.1 million from $7.6 million, driven by a $14.2 million cumulative catch-up adjustment tied to updated future costs.
R&D expenses fell to $18.5 million from $21.8 million, while G&A costs eased to $6.4 million from $6.9 million.
FHTX•
